Due to the North China Pharmaceutical Company.Ltd(600812) (600812) hot search of centralized mining and supply interruption, the operating performance has basically stagnated in the past two years. In order to find performance growth points, North China Pharmaceutical Company.Ltd(600812) last year, in addition to normally promoting drug R & D and listing, it also set foot in new tea drinks across the border.
net profit is expected to decline by nearly 80% last year
On January 14, North China Pharmaceutical Company.Ltd(600812) (600812) released the performance forecast. It is estimated that the net profit attributable to the shareholders of the listed company will be about 20 million yuan in 2021, a decrease of about 77.32 million yuan or 79.45% year-on-year compared with the same period in 2020 (statutory disclosure data).
The net profit in 2021 is quite different from that in 2020, which is mainly affected by government subsidies. In 2021, North China Pharmaceutical Company.Ltd(600812) non recurring profit and loss items such as government subsidies included in the current profit and loss decreased by about 80 million yuan, mainly due to the receipt of 79.44 million yuan of stabilization funds in the same period of 2020.
In August 2021, the news that North China Pharmaceutical Company.Ltd(600812) cut off the supply of ibuprofen sustained-release capsules and was included in the list of violations once climbed to the hot search list. From the performance forecast, North China Pharmaceutical Company.Ltd(600812) the operating performance in 2021 is stagnant, and the loss is basically the same as that in 2020.
If the above government subsidy funds are excluded, the performance of North China Pharmaceutical Company.Ltd(600812) in 2021 is basically the same as that in 2020. The company expects to deduct non net profit loss of about 59 million yuan in 2021, an increase of 2.9 million yuan over 2020.
North China Pharmaceutical Company.Ltd(600812) said that in the face of the impact of covid-19 epidemic in Gaocheng District, Shijiazhuang city and the complex situation of superposition of multiple internal and external adverse factors, the company deepened internal reform, adjusted business structure and focused on the development of biotechnology drugs and biotechnology products. It is expected that the net profit after deducting non recurring profits and losses attributable to the shareholders of the listed company will be basically the same as that in 2020.
In terms of drug research and development, at the end of December last year, North China Pharmaceutical Company.Ltd(600812) Hebei Huamin Pharmaceutical Co., Ltd. “ceftriaxone sodium for injection (0.25g / 1.0g)” was approved by the drug evaluation center of the State Drug Administration and passed the consistency evaluation of generic drug quality and efficacy.
It is reported that ceftriaxone sodium for injection is one of the key products of anti infective drugs of Huamin company. It belongs to the national medical insurance catalogue and is mainly used to treat the infection caused by pathogenic bacteria sensitive to this product.
However, the application of recombinant human anti rabies virus monoclonal antibody injection is not smooth. There are two specifications for the registration application of class I new drug recombinant human anti rabies virus monoclonal antibody injection declared by the subordinate new drug company of North China Pharmaceutical Company.Ltd(600812) , of which the application of 500 IU / 2.5ml specification has been voluntarily withdrawn, and the registration application of 200 IU / 1.0ml specification is still being accepted.
cross border selling of “milk tea”
For two consecutive years, the performance has stood still. In order to seek performance growth points, North China Pharmaceutical Company.Ltd(600812) began to cross-border set foot in new tea drinks.
In 2021, North China Pharmaceutical Company.Ltd(600812) Hebei Huawei Health Industry Co., Ltd., 51% owned by North China Pharmaceutical Company.Ltd(600812) , launched the milk tea brand “Zhen Yinzi” and innovated the combination of “scientific water + five element secret recipe” series of health preserving national tide drinks.
Huawei health is a health consumer brand under North China Pharmaceutical Company.Ltd(600812) . Besides these new tea drinks, it also has lutein ester products, small molecule peptides, fructose oligosaccharides, probiotics, protein powder, wine, acacia, Pueraria flower Poria tablets, air disinfectant gel and other products.
According to official account China Wei, ” North China Pharmaceutical Company.Ltd(600812) healthy city” revealed that Zhen Yin Zi should build a very Chinese brand, and the reason why it was called Zhen Yin Zi was because it was a popular health drink in Tang Dynasty. In the riverside map of Qingming, there are booths with sunshade to sell “drink” and “fragrant drink”, that is, the beverage shop in Song Dynasty.
In August 2021, North China Pharmaceutical Company.Ltd(600812) official wechat published the article “healthy tide drink” Zhen Yinzi “landed on Tanabata and Wanda in Chang\’an was popular”. It said that the trial operation on the first day achieved a single store revenue of nearly 8000 yuan, which won a good start for the opening of new stores in the future.
According to the disclosure of ” North China Pharmaceutical Company.Ltd(600812) health city”, Zhen Yinzi is the key project of the company’s terminal channel construction in 2022, hoping to build a new benchmark in the national tide beverage industry.
New tea drinks are favored by young people, and many traditional pharmaceutical enterprises began to set foot in this field.
In addition to North China Pharmaceutical Company.Ltd(600812) , time-honored pharmacies Beijing Tongrentang Co.Ltd(600085) were also popular for selling coffee and milk tea. Beijing Tongrentang Co.Ltd(600085) the new healthy retail business “Zhima health”, the offline experience store has provided licorice latte, cinnamon cappuccino, lung moistening tea, black medlar grapefruit and other drinks.
